This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
News|Articles|May 15, 2014
- Pharmaceutical Technology-05-15-2014
- Volume 2014 eBook
- Issue 2
Optimizing the Sterilization of Liquids in Sealed Containers
Author(s)Jordi Net
sterilization approach-cycles controlled by differential pressure-is described.
Advertisement
Establishing a sterilization process for liquids in containers involves trial and error, as pressure adjustments must be made during the heating, sterilization, and cooling phases. An alternate approach-cycles controlled by differential pressure-maintains the pressure in the chamber at a level that prevents the rigid containers from exploding and the non-rigid containers from becoming deformed.
Download
.
Articles in this issue
over 12 years ago
Potential Benefits Drive Interest in Continuous Manufacturingover 12 years ago
Continuous Bioprocessing Challengesover 12 years ago
Using Modular Systems in Biopharmaceutical Manufacturingover 12 years ago
Determining Protein Oxidation Induced During Fill-Finish Operationsover 12 years ago
Single-Use Technology in Parenteral Fill/FinishAdvertisement
Related to this article
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
AI can turn medical device risk management into a continuous signal.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
Advertisement
Advertisement